FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Wolchko J Scott				uer Name and Tick E THERAPE			Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
	(First) ERAPEUTICS, II S SUMMIT DRI			e of Earliest Transa 1/2022	action (Month/	Day/Year)	X Officer (give title below) President and CEO					
(Street) SAN DIEGO	CA	92131	4. If A	mendment, Date of	Original Filed	(Month/Day/Year)	6. Indiv Line)	idual or Joint/Group Form filed by One Form filed by Mor Person	Reporting Pers	on		
(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4		5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		

Reported Transaction(s) (Instr. 3 and 4) (Instr. 4) (A) or (D) Code Amount Price M⁽¹⁾ Common Stock 07/21/2022 30,000 A \$2.7 461,546 D **S**(1) 10.829 \$32.54(2) D 07/21/2022 D 450.717 Common Stock 07/21/2022 $S^{(1)}$ 19,171 D \$33.07(3) 431,546 D Common Stock $M^{(1)}$ 07/22/2022 437,792 D Common Stock 6,246 Α \$2.7 $S^{(1)}$ D \$31.33(4) 434,869 Common Stock 07/22/2022 2.923 D 07/22/2022 $S^{(1)}$ D \$32.61(5) 432,166 D Common Stock 2,703 07/22/2022 $S^{(1)}$ 620 D \$33.28(6) 431.546 D Common Stock

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$2.7	07/21/2022		M ⁽¹⁾			30,000	(7)	01/03/2027	Common Stock	30,000	\$0.00	6,246	D	
Stock Option (Right to Buy)	\$2.7	07/22/2022		M ⁽¹⁾			6,246	(7)	01/03/2027	Common Stock	6,246	\$0.00	0	D	

- 1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.
- 2. Represents the weighted average sale price of the shares sold ranging from \$31.82 to \$32.81 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 6.
- 3. Represents the weighted average sale price of the shares sold ranging from 32.83 to 33.33 per share.
- 4. Represents the weighted average sale price of the shares sold ranging from \$30.99 to \$31.74 per share.
- 5. Represents the weighted average sale price of the shares sold ranging from \$32.02 to \$33.01 per share.
- 6. Represents the weighted average sale price of the shares sold ranging from \$33.03 to \$33.67 per share.
- 7. This option is fully vested.

Remarks:

/s/ Cindy Tahl, as Attorney-in-**Fact**

07/25/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.